📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Valneva

1.1 - Company Overview

Valneva Logo

Valneva

Headquarter: France
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of prophylactic vaccines for infectious diseases, focusing on development and commercialization for unmet medical needs. Portfolio includes IXCHIQ (VLA1553), a live-attenuated, single-dose chikungunya vaccine approved in the U.S.; VLA15, a multivalent Lyme disease vaccine in Phase 3; and a tetravalent Shigella vaccine candidate developed with LimmaTech.

Products and services

  • VLA1553 (Chikungunya Vaccine): A live-attenuated, single-dose, U.S.-approved vaccine that prevents mosquito-borne chikungunya and is under regulatory review in other regions
  • VLA15 (Lyme Disease Vaccine): A multivalent recombinant protein, Phase 3 vaccine candidate targeting Borrelia bacteria to prevent Lyme disease, a tick-borne illness
  • Tetravalent Shigella Vaccine Candidate: A tetravalent vaccine candidate, developed with LimmaTech, aiming to prevent Shigella infections that cause bacterial dysentery

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Valneva

PaxVax Logo

PaxVax

HQ: United States Website
  • Description: Provider of candidate oral vaccines for influenza and other key infectious diseases, using a proprietary adenovirus-based oral vaccine technology that addresses delivery hurdles of traditional injectable vaccines, including the need for cold storage and needles.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full PaxVax company profile →
Sunshine Biopharma Logo

Sunshine Biopharma

HQ: United States Website
  • Description: Provider of research, development, and commercialization of drugs for the treatment of various forms of cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sunshine Biopharma company profile →
Agenovir Logo

Agenovir

HQ: United States Website
  • Description: Provider of novel antiviral therapeutics for diseases associated with viral reservoirs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Agenovir company profile →
Ansun BioPharma Logo

Ansun BioPharma

HQ: United States Website
  • Description: Provider of host-directed antivirals and solid tumor therapies. Offers DAS181, a recombinant sialidase that removes sialic acids from respiratory epithelial cells to block viral entry and treat parainfluenza and influenza. Develops multi-modality platforms targeting tumor and immune cells to prevent immune escape and restore tumor surveillance, including oncolytic viruses, bispecific antibodies, and CAR-NK/γδ T cells.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ansun BioPharma company profile →
Amplyx Logo

Amplyx

HQ: United States Website
  • Description: Provider of pre-clinical small-molecule therapeutics for debilitating and life-threatening diseases in patients with compromised immune systems, employing a platform approach that enhances efficacy and lowers toxicity by adding a second small molecule to existing drugs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Amplyx company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Valneva

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Valneva

2.2 - Growth funds investing in similar companies to Valneva

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Valneva

4.2 - Public trading comparable groups for Valneva

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Valneva

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Valneva

What does Valneva do?

Valneva is a provider of prophylactic vaccines for infectious diseases, focusing on development and commercialization for unmet medical needs. Portfolio includes IXCHIQ (VLA1553), a live-attenuated, single-dose chikungunya vaccine approved in the U.S.; VLA15, a multivalent Lyme disease vaccine in Phase 3; and a tetravalent Shigella vaccine candidate developed with LimmaTech.

Who are Valneva's competitors?

Valneva's competitors and similar companies include PaxVax, Sunshine Biopharma, Agenovir, Ansun BioPharma, and Amplyx.

Where is Valneva headquartered?

Valneva is headquartered in France.

How many employees does Valneva have?

Valneva has 1,000 employees 🔒.

When was Valneva founded?

Valneva was founded in 2010 🔒.

What sector and industry vertical is Valneva in?

Valneva is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Valneva

Who are the top strategic acquirers in Valneva's sector and industry

Top strategic M&A buyers and acquirers in Valneva's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Valneva?

Top strategic M&A buyers groups and sectors for Valneva include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Valneva's sector and industry vertical

Which are the top PE firms investing in Valneva's sector and industry vertical?

Top PE firms investing in Valneva's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Valneva's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Valneva's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Valneva's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Valneva include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Valneva's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Valneva?

The key public trading comparables and valuation benchmarks for Valneva include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Valneva for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Valneva with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Valneva's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Valneva with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Valneva's' sector and industry vertical?

Access recent funding rounds and capital raises in Valneva's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Valneva